This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

Hi guys, just bought in this morning, wish it is not too late. happy easter to everyone. ;-)

mitzy - I think potential being the operative word.
It has the potential to generate $75m annually from the NHL Lymphoma.
It has the potential to generate $500m annually revenues from Ruthenium.
It has the potential to generate $420m+ annually from VIR5103 HIV Ribozyme.
It has the potential to generate $xxxx from Genvax Prostate cancer vaccine ,Genvax Colon cancer vaccine, Hepatitis B Ribozyme, Asthma Ribozyme, Arthritis Ribozyme......

Lots of ifs but also lots of potential which of course has value even in early stage. The risk declines as the portfolio increases.
Just need one of those to come in.
Also bear in mind Pfizer paid $6bn for Ageron to get hold of their Vircept HIV product and you begin to see the potential.

Great day again. Wish we could close over 3 quid.

cheers GF.

it's creating a little resistance, but I reckon it will push through it no prob next week

Added again at 285p and 283p. We usually get a mad rush at the very end on the last trading day of the week with this one and tomorrow its good friday and we are closed.

cheers GF.

From the Mike Walters site............

Michael Walters tipping it again today, he himself bought more this morning. He ends his piece by saying, 'There could be much more to come as the world wakes up to the achievements of Dr Stevenson and her team.' - I must admit the announcement was too good for me to ignore and I have bought some MMG today also. I think we will all be looking very, very good on this stock in a small time. Cancer is such a huge killer and although there are many companies that have made big advances, the one recently announced by this company seems to have attracted not only investors attention but apparently, the attention of some major pharmaceutical companies. Licencing revenues from some of its drugs could bring in multpiles of the current market price on an annual basis. Is the pie in the sky stuff? Absolutely, but there is so much going on here and Im pretty sure we will see further news releases and updates, I just had to take a few for myself. I think this one is going to run and run

cheers GF

edited out.

I read it again .

Some information about Edinburgh University,

MMI has recently entered into an agreement with this university.

Andrew Bolger writing in the Financial Times today on the commercialisation of Edinburgh Universities impressive research output, claims that it has created more than 47 companies from its research activities over the past five years, of which 37 are still trading. He also states that it is Scotlands biggest (and) is one of the UKs top-rated research institutions>>>>>>

Further it is involved with local health and development authorities to develop a 250m biomedical research park in the city>>>>>

It is expected to create more than 5,000 jobs.

cheers GF

Goldfinger you shouldnt be copying info from a subscription site. If people want that info then they should pay like the rest of us. You will end up getting yourself banned.There was hell to play when MW thought a poster from advfn had copied his article.As it happened he had not,just posted the subscription link.

moving nicely again now ...just about to hit the 3. Looks like the resistance is less this time

That's fair comment momentum.

It is obviously well worth the 75.

Cheap in fact.

Momentum you are horribly wrong, I have not copied info from a subscription site. I indeed copied the article from a free B/Board, and I am not a member of Mike Walters site. I think that you will find I am not in breach of the copywrite laws.

cheers GF.

Nice to see this one near the 3 quid mark. Come on just a little bit further.

cheers GF.

Well a fantastic week here and just about everywhere else. Hope everyones happy with their gains. Should be a lot more to come. Going for a pint now to celebrate.

Happy Easter to every one.

cheers GF.

Damn right Im happy. Cheers GF. Im off to do the same.

Me too. Have a good one people.

MS

I'm off shopping before the rush.. bye for now.

Shot-in-the-arm for firm

Success with an anti-cancer vaccine has almost quadrupled the value of Cambridge-based MMI since the beginning of the year, making the company worth 115 million.


Massive success: Founder David Best The biggest rise has come this week following results of clinical trials involving cancer patients suffering from lymphoma, but the new vaccine is expected to help with other forms of cancer as well, including lung.

The vaccine has been developed by Genvax. MMI owned 50 per cent, but this week increased its holding to 58 per cent.

The further investment comes as MMI's share price rockets yesterday it put on more than 38p, lifting to nearly 3. At the beginning of this year the shares were trading at under 60p.

The vaccine uses tetanus toxin to boost the immune response against cancer.

Known as a DNA fusion gene vaccine, it has been trialled on lymphoma patients for three years, with most responding well.

Patients with myeloma, cancer of the bone marrow, are now being given the vaccine, and the next in line are those suffering from prostate and colon cancer, and other solid tumours such as lung or stomach cancer.

Genvax has now clinched an exclusive worldwide licence with Cancer Research Technology to commercialise rights to the vaccine, which was invented by Prof Freda Stevenson at the University of Southampton.

MMI, which is based in Cowley Road, Cambridge, is putting more funds into Genvax to take the vaccine forward.

David Best, founder and boss of MMI, said: "Cancer is now the main cause of premature death in the western world.

"By working with the major cancer charities, the world class research team at the University of Southampton and the National Blood Service, together we now have the potential to improve the lives of patients with cancer and to keep the UK at the forefront of medicine."

MMI, which is listed on the London stock market, specialises in funding and commercialising breakthrough treatments developed within NHS hospital trusts.

24 March 2005

http://www.cambridge-news.co.uk/business/news/2005/03/24/2e2594a7-72b3-4155-bcc4-b2bd6aa76ed0.lpf